New Directions With PARP Inhibitors in Pancreatic Cancer

CCO Oncology Podcast

English - February 21, 2022 18:35 - 18 minutes - 17.3 MB
Courses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples

Next Episode: TKIs for Advanced HCC in the Second Line and Beyond

In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

Current treatment landscape and testing in the United States vs the United Kingdom Testing for molecular subgroups beyond BRCAmUsing PARP inhibitors in earlier stages of the diseaseLearning from other cancers, such as prostate, breast, and ovarian

Presenters:

Eileen M. O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College
New York, New York, USA

Naureen Starling, MD, FRCP
Associate Director of Clinical Research
Department of GI Cancers
Consultant Medical Oncologist, GI Cancers
The Royal Marsden Hospital
London, United Kingdom

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program:
https://bit.ly/3s6AnSz